Incidence of illnesses linked to hypogonadism is anticipated to rise during the forecast period, propelling market expansion. For instance, according to the Endocrine Society (January 2022), hypogonadism is a prevalent disorder in males worldwide, and it is more common in older men, obese men, and those with type 2 diabetes. Over the course of the forecast period, rising infertility rates around the world are anticipated to fuel market expansion for human chorionic gonadotropin (HCG). For instance, the report published in Galadari Printing and Publishing LLC, 2018, found that the prevalence of infertility increased along with a notable decline in demographics, with the number of births per woman falling from 6.6 in the 1970s to 5.22 in the 1980s and 1985 to 1.73 from 2015 to 2020, a decline that totaled a 160% drop.
Global Human Chorionic Gonadotropin (HCG) Market is estimated to be valued at US$ 710.88 Million in 2022 and is expected to exhibit a CAGR of 6.5% during the forecast period (2022-2030).
Prominent Players in the Human Chorionic Gonadotropin (HCG) Industry:
1. Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
2. Ferring B.V.
Frederik and Eva Paulsen founded the company in the 1950s. It has headquarters situated in Saint-Prex, Switzerland. In June, 2022, the biopharmaceutical company Ferring B.V. announced a strategic partnership with the innovation-focused global biopharma company I-MAB Biopharma Co., Ltd. to advance the development of olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and associated inflammatory conditions.
3. Lupin
Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company is operational in more than 100 countries.
More than 100 countries. Lupin Limited (Lupin) in the month of December, 2022 announced the launch of authorized generic version of PENNSAID® (Diclofenac Sodium Topical Solution), 2% w/w of Horizon Pharma Therapeutics in the United States.